Skip to content

State coverage

Arkansas

State Medicaid · 5 documents cited

Medicaid, for obesity: Covers with conditions. The conditions and the appeal deadline are in the summary below.

At a glance

Covers with conditions
Medicaid, for obesity
Weight loss alone is excluded; Wegovy is covered for heart risk and liver disease, Zepbound for sleep apnea.
Appeal deadline
30 calendar days from the date of written notice, and the 30 days does not start counting until 5 days after that date source
Primary source
Arkansas Department of Human Services, Division of Medical Services, Arkansas Medicaid Preferred Drug List (PDL)
Date read
September 2026

Denise Ramirez, Coverage Editor · Who writes this site

Arkansas Medicaid says the same sentence in three separate criteria documents, almost word for word: it does not cover these drugs for weight loss alone. That sentence is not a throwaway — it is followed each time by a narrow, unrelated diagnosis that IS covered, which makes Arkansas one of the more specific conditional states on this site rather than a flat exclusion.

Wegovy has two such carve-outs, added over a year apart. An August 2024 prior-authorization memo covers it for reducing cardiovascular risk in a patient with established heart disease and a qualifying BMI — the same cardiovascular-outcomes indication Medicare and several other Medicaid programs use. A November 2025 memo adds a second, unrelated one: Wegovy for confirmed liver fibrosis from metabolic dysfunction-associated steatohepatitis (MASH), which has nothing to do with a scale reading and requires a liver biopsy or two separate non-invasive fibrosis tests to document.

Zepbound gets one carve-out, narrower still: obstructive sleep apnea, and only obstructive sleep apnea. The May 2025 criteria require a diagnosed AHI of 15 or more on a sleep study, a specialist prescriber, and — pointedly — six months of documented, unsuccessful CPAP compliance before the drug can be added rather than substituted for the CPAP machine.

The state's Preferred Drug List reflects the same split: its "Antidiabetic Agents – GLP-1 Receptor Agonists" class, revised July 1, 2026, lists Trulicity and Victoza as preferred and Mounjaro, Ozempic, Rybelsus and Xultophy as non-preferred — all diabetes brands. Wegovy and Zepbound do not appear on the PDL itself; they are handled entirely through the manual-review criteria quoted below, outside the preferred/non-preferred structure.

What we could verify for Arkansas

The state's diabetes GLP-1 class on the PDL never mentions weight loss and never lists Wegovy or Zepbound: "ANTIDIABETIC AGENTS – GLP-1 RECEPTOR AGONISTS... PREFERRED AGENTS: TRULICITY (dulaglutide)*, VICTOZA (liraglutide)* – BRAND ONLY. NON-PREFERRED AGENTS: exenatide (generic for BYETTA), liraglutide (generic for VICTOZA), MOUNJARO (tirzepatide), OZEMPIC (semaglutide), RYBELSUS (semaglutide), SOLIQUA (lixisenatide/insulin glargine), XULTOPHY (insulin degludec/liraglutide)."

Arkansas Department of Human Services, Division of Medical Services, Arkansas Medicaid Preferred Drug List (PDL), effective July 2026 · source

Wegovy's first carve-out is cardiovascular, not weight-related, and says so up front: "NOTE: Arkansas Medicaid does not currently cover medications solely for the use of weight loss. PA requests for this medication must demonstrate that the patient has established cardiovascular disease and at risk for a major cardiovascular event." Approval requires a history of heart attack, stroke, stent, bypass or symptomatic peripheral arterial disease, plus a BMI of 27 or higher, and excludes anyone "[r]equested for weight loss only."

Arkansas Department of Human Services, Division of Medical Services, Pharmacy Program memorandum (AR Medicaid DUR Board, July 17, 2024 meeting), effective August 2024 · source

Zepbound's only covered use is sleep apnea, and the memo repeats the same disclaimer before laying out the criteria: "Arkansas Medicaid does not cover medications solely for weight loss. The criteria listed below pertain to the obstructive sleep apnea indication only." It requires "moderate to severe obstructive sleep apnea (OSA) defined as apnea-hypopnea index (AHI) ≥15... based on polysomnography," a specialist prescriber, and denies anyone who "[h]as not been on a weight management program for at least 6 months" or is "[r]equested for weight loss only."

Arkansas Department of Human Services, Division of Medical Services, Pharmacy Program memorandum (AR Medicaid DUR Board, April 16, 2025 meeting), effective May 2025 · source

A third, later memo adds a liver-disease carve-out for Wegovy specific to advanced fibrosis, again ruling out a plain weight-loss request: the beneficiary "must be diagnosed with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis," documented by biopsy or two separate fibrosis tests, prescribed with a liver specialist, and "[p]rior authorization request should not be for weight loss only."

Arkansas Department of Human Services, Division of Medical Services, Pharmacy Program memorandum (AR Medicaid DUR Board, October 15, 2025 meeting), effective November 2025 · source

Arkansas beneficiaries get 30 days to appeal, and the manual is explicit that the clock does not start on the notice date itself: "the beneficiary may appeal. The appeal request must be in writing and submitted to the Department of Human Services, Appeals and Hearings Section... The appeal request must be received by the Appeals and Hearings Section no later than thirty (30) days from the date of written notice. The thirty (30) days begins to run five (5) days after the date of written notice."

Arkansas Department of Human Services, Medicaid Provider Manual, Section 191.004 (Administrative Appeals), effective June 2025 · source

Medicaid is only one of the routes. If you have a commercial or employer plan, the rules are different and are on the employer plans page; Medicare has a federal rule of its own, on the Part D page.

If the appeal fails, or you cannot wait

Cash-pay telehealth is the fallback, not the bargain: you pay the whole cost yourself, and a covered prescription is almost always cheaper than any of these. Use this route when coverage has actually been exhausted, or when you need to start while an appeal runs.

Companies that pay this site a commission, what we found on each one's own site, and a link to check availability
CompanyWhat we found on its own site
CoreAge RxCheck availabilityAdvertises $99 a month for compounded semaglutide, flat across doses. Read the terms before you sign up: the lander our link opens has shown $149 rather than $99, and a consultation fee can be charged on top and may not be refundable.
OakCheck availabilityFlat price across doses, free shipping with supplies.
Care Bare RxCheck availabilityNames its pharmacies with addresses; sells brand Ozempic as well as compounded.
Gala HealthCheck availabilityAll doses one price, but the advertised rate needs a yearly subscription.
Synergy RxCheck availabilityProviders licensed in your state; publishes no GLP-1 price before the consult.
Breeze MedsCheck availabilityServes all 50 states; publishes a starting price only.
Direct MedsCheck availabilityNo monthly membership, and one price at every dose. The lander our link opens starts at $147 and reads its own discount two ways on the same screen: the banner across the top says $150 off, the product tiles below it say up to $200 off.
FoundCheck availabilityBills the clinical visits through insurance where it is in network, with the medication charged separately. Read its Medicare Part D route closely: it advertises brand GLP-1s from $50 a month, and the footnote under that offer says the $50 does not count toward your Part D deductible or out-of-pocket maximum, and that Extra Help does not apply.
EdenCheck availabilityTwo different prices for the same drug depending on which door you come in. The lander our link opens advertises $99 a month for semaglutide, held at every dose, with no membership fee. Eden's own weight-loss page, read the same day, offers it from $99 a month plus an Eden Membership, and the footnote there says the membership is $39 the first month and $99 after, and that medication is not available without one.
ShedRxCheck availabilityPublishes no price before the questionnaire: you answer it, pick a plan and see the cost at checkout. Sells injections plus needle-free drops and lozenges, and a footnote on the same page names sixteen states where the oral forms are not available.
TrimiCheck availabilityCompounded tirzepatide at $125 a month and semaglutide at $99, each on the annual plan and each the same price at every dose. One membership covers the medication, the clinician visits and shipping.
He & She MDCheck availabilityAdvertises semaglutide from $99 a month and charges only if a prescription is written. The printed tiers are higher than the headline: $139 a month on six months, billed $834 at once, and $149 a month on three. GLP-1s ship to every state except Louisiana.
HealthRXCheck availabilityCompounded semaglutide from $133 a month on a three-month plan and as low as $99 on twelve; tirzepatide from $209, as low as $179. ⚠ The page states its member reviews are illustrative composites rather than real patients.
Pallas HealthCheck availabilityCompounded semaglutide at $139 for the first month and then $597 every twelve weeks, and tirzepatide at $179 then $897. ⚠ The page discloses that some of its content is AI-generated and that its imagery uses models rather than patients.
MEDGmCheck availabilityGLP-1 injections from $179 and tablets from $249, with brand-name options priced as a membership plus the cost of the drug — $99 for Zepbound or Wegovy, $171 for Ozempic. ⚠ It discloses AI-generated content and actor imagery beside more than twenty named patient testimonials.
Bodybuilding Health+Check availabilityCompounded tirzepatide runs $174.67 to $209 a month depending how many months are bought at once, and semaglutide is tiered the same way. ⚠ The program is listed as Bodybuilding.com; the page this link opens brands itself Bodybuilding Health+ and is operated by Dynamo Group LLC.
Strut HealthCheck availabilityA multi-category telehealth storefront — sexual health, testosterone, hair, skin, peptides, menopause — where weight loss is one tile among six. It publishes no price for a GLP-1, or for anything else, on the page this link opens.
RxSpan MDCheck availabilityMulti-category telehealth that promises transparent pricing and no hidden fees, and then publishes no price at all — not for a GLP-1 and not for any other product — on the page this link opens.

Prices in those notes were read from each company's own site in August 2026 and September 2026, and they change often. Check the current number before you buy.

Where this comes from

  1. Arkansas Department of Human Services, Division of Medical Services, Arkansas Medicaid Preferred Drug List (PDL), effective July 2026 — ar.primetherapeutics.com/documents/d/arkansas/crm-attachment_pdl-documen
  2. Arkansas Department of Human Services, Division of Medical Services, Pharmacy Program memorandum (AR Medicaid DUR Board, July 17, 2024 meeting), effective August 2024 — humanservices.arkansas.gov/wp-content/uploads/PharmMemo8-14-24.pdf
  3. Arkansas Department of Human Services, Division of Medical Services, Pharmacy Program memorandum (AR Medicaid DUR Board, April 16, 2025 meeting), effective May 2025 — humanservices.arkansas.gov/wp-content/uploads/PharmMemo-5-14-25.pdf
  4. Arkansas Department of Human Services, Division of Medical Services, Pharmacy Program memorandum (AR Medicaid DUR Board, October 15, 2025 meeting), effective November 2025 — humanservices.arkansas.gov/wp-content/uploads/PharmMemo11-12-25.pdf
  5. Arkansas Department of Human Services, Medicaid Provider Manual, Section 191.004 (Administrative Appeals), effective June 2025 — humanservices.arkansas.gov/wp-content/uploads/Final-Posting-Packet-Medic

Every state we have verified is in the coverage matrix. Appeal routes and deadlines are on the procedures page.